Production Method 1

632324-41-5

928715-37-1

Reaction Conditions

1.1 Reagents: Aluminum chloride Solvents: Dichloromethane ;  0 °C; 15 min, rt; rt → -70 °C
1.2 Solvents: Dichloromethane ;  4 h, -40 °C
1.3 Reagents: Ammonium chloride Solvents: Water

Reference

Preparation of indazolyl-substituted sulfonamides and analogs as glucocorticoid receptor modulators in the treatment of inflammatory diseases

, World Intellectual Property Organization, , ,

Production Method 2

1232407-68-9

928715-37-1

Reaction Conditions

1.1 Reagents: Sodium bicarbonate ,  Dess-Martin periodinane Solvents: Dichloromethane ;  45 min, 0 °C
1.2 Reagents: Sodium bicarbonate ,  Sodium thiosulfate Solvents: Water

Reference

Intramolecular Alkene-Alkene Coupling via Rh(III)-Catalyzed Alkenyl sp2 C-H Functionalization: Divergent Pathways to Indene or α-Naphthol Derivatives

Maraswami, Manikantha; Diggins, Thomas; Goh, Jeffrey; Tio, Raymond; Ong, Wan Qing Renee; et al, ACS Catalysis, 2021, 11(18), 11494-11500

1-(2-bromo-6-fluorophenyl)ethan-1-one Raw materials

• 1-(2-bromo-6-fluorophenyl)ethan-1-ol
• SILANE, (2-BROMO-6-FLUOROPHENYL)TRIMETHYL-

1-(2-bromo-6-fluorophenyl)ethan-1-one Preparation Products

• 1-(2-bromo-6-fluorophenyl)ethan-1-one (928715-37-1)

• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 3. Enantiomeric two-fold interpenetrated 3D zinc(ii) coordination networks as a catalytic platform: significant difference between water within the cage and trace water in transesterification?
  Eunkyung Choi,Minjoo Ryu,Haeri Lee,Ok-Sang Jung Dalton Trans., 2017,46, 4595-4601
• 4. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Recent Advances in the Study of 1-(2-bromo-6-fluorophenyl)ethan-1-one (CAS: 928715-37-1) and Its Applications in Chemical Biology and Pharmaceutical Research

1-(2-bromo-6-fluorophenyl)ethan-1-one (CAS: 928715-37-1) is a fluorinated aromatic ketone that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various biologically active molecules, including potential drug candidates. The presence of both bromo and fluoro substituents on the phenyl ring enhances its reactivity, making it a valuable building block for further chemical modifications. Recent studies have explored its utility in the development of novel therapeutic agents, particularly in the fields of oncology and neurology.

One of the most notable applications of 1-(2-bromo-6-fluorophenyl)ethan-1-one is its role in the synthesis of kinase inhibitors. Kinases are critical targets in cancer therapy, and the ability to modulate their activity has profound implications for drug development. Researchers have utilized this compound to design and synthesize small-molecule inhibitors that selectively target specific kinase pathways. For instance, a recent study published in the Journal of Medicinal Chemistry demonstrated the efficacy of a derivative of 1-(2-bromo-6-fluorophenyl)ethan-1-one in inhibiting the activity of a kinase implicated in glioblastoma multiforme, a highly aggressive form of brain cancer. The study reported promising in vitro and in vivo results, highlighting the potential of this compound as a scaffold for further optimization.

In addition to its applications in oncology, 1-(2-bromo-6-fluorophenyl)ethan-1-one has also been investigated for its potential in neurological disorders. A study published in ACS Chemical Neuroscience explored its use in the synthesis of compounds targeting the GABAergic system, which is implicated in conditions such as epilepsy and anxiety. The researchers found that derivatives of this compound exhibited significant binding affinity to GABA receptors, suggesting their potential as novel anxiolytic or anticonvulsant agents. These findings underscore the versatility of 1-(2-bromo-6-fluorophenyl)ethan-1-one as a building block for the development of central nervous system (CNS)-active drugs.

The synthetic routes to 1-(2-bromo-6-fluorophenyl)ethan-1-one have also been a subject of recent research. Traditional methods often involve multi-step processes with low yields and poor selectivity. However, advancements in catalytic chemistry have led to the development of more efficient and sustainable synthetic protocols. A recent publication in Organic Process Research & Development described a novel palladium-catalyzed cross-coupling reaction that significantly improves the yield and purity of 1-(2-bromo-6-fluorophenyl)ethan-1-one. This method not only reduces the environmental impact of the synthesis but also enhances the scalability of the process, making it more suitable for industrial applications.

Despite its promising applications, challenges remain in the utilization of 1-(2-bromo-6-fluorophenyl)ethan-1-one. Issues such as stability under physiological conditions and potential toxicity profiles of its derivatives need to be addressed. Ongoing research is focused on optimizing the pharmacokinetic and pharmacodynamic properties of compounds derived from this scaffold. For example, a recent study in Bioorganic & Medicinal Chemistry Letters reported the development of prodrugs based on 1-(2-bromo-6-fluorophenyl)ethan-1-one, which exhibit improved bioavailability and reduced off-target effects. These advancements are critical for translating preclinical findings into clinically viable therapeutics.

In conclusion, 1-(2-bromo-6-fluorophenyl)ethan-1-one (CAS: 928715-37-1) represents a valuable chemical entity with broad applications in drug discovery and development. Recent studies have highlighted its potential in oncology and neurology, as well as advancements in its synthetic methodologies. As research continues to uncover new opportunities for this compound, it is expected to play an increasingly important role in the development of next-generation therapeutics. Future directions may include exploring its use in combination therapies and further optimizing its derivatives for enhanced efficacy and safety.

• 693285-70-0(1-Propanone, 1-(2-bromo-6-fluorophenyl)-2-methyl-)
• 479676-25-0(1-BUTANONE, 1-(2-BROMO-6-FLUOROPHENYL)-)
• 1807055-61-3(2',3'-Dibromo-6'-fluoroacetophenone)
• 1542563-93-8(1-(6-bromo-2,3-difluorophenyl)ethan-1-one)
• 625446-22-2(1-(4-bromo-2-fluorophenyl)ethan-1-one)
• 1006-39-9(1-(2-bromo-4-fluorophenyl)ethan-1-one)
• 1514581-21-5(1-(2-bromo-6-fluoro-3-methylphenyl)ethan-1-one)
• 1805122-12-6(1-(2,4-Dibromo-6-fluorophenyl)ethanone)
• 1805119-78-1(2'-Bromo-4',6'-difluoroacetophenone)
• 1807029-26-0(2'-Bromo-3',6'-difluoroacetophenone)